US Food and Drug Administration Awards $2.6 Million Orphan Products Development Grant for Expanded Study of HyBryte^™ in the Treatment of Cutaneous T Cell Lymphoma

Soligenix, Inc. announced that the US FDA has awarded an Orphan Products Development grant to support the evaluation of HyBryte™ for expanded treatment in patients with early-stage cutaneous T cell lymphoma.